Patent search ipc:"A61K31/16" Page 1

1.

发明授权
Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms 有权

公开(公告)号：US12178794B2

公开(公告)日：2024-12-31

申请号：US18074711

申请日：2022-12-05

Applicant: THE WILLIAM M YARBROUGH FOUNDATION

Inventor： Michael E. Silver

IPC: A61K31/26 , A61K9/00 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/277 , A61K31/513 , A61K45/06 , A61P35/00

Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.

2.

发明授权
Sleep disorder treatment and prevention 有权

公开(公告)号：US12171762B2

公开(公告)日：2024-12-24

申请号：US18152399

申请日：2023-01-10

Applicant: Purdue Pharma L.P.

Inventor： Stephen C. Harris , Ram P. Kapil , Donald J. Kyle , Garth Whiteside

IPC: A61K31/498 , A61K9/00 , A61K31/138 , A61K31/145 , A61K31/16 , A61K31/197 , A61K31/485 , A61K31/554 , A61K31/7048 , A61P25/20 , A61P25/32

Abstract: The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.

3.

再颁专利
Method of treatment of hypoxia inducible factor (HIF)-related conditions 有权

公开(公告)号：USRE50230E1

公开(公告)日：2024-12-10

申请号：US17824596

申请日：2022-05-25

Applicant: GRIFOLS WORLDWIDE OPERATIONS LIMITED

Inventor： David A. Ross , Ralph Christian Crumine

IPC: A61K38/40 , A61K31/16 , A61K31/164 , A61K31/198 , A61K31/223 , A61K31/4196 , A61K31/426 , A61K31/4412 , A61K31/4704 , A61K31/472 , A61K45/06 , A61P9/10 , A61P25/28 , A61P39/04

Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.

4.

发明授权
Compositions and methods for enhancing immune response to vaccination and improving vaccine production 有权

公开(公告)号：US12144856B2

公开(公告)日：2024-11-19

申请号：US16738692

申请日：2020-01-09

Applicant: Versitech Limited

Inventor： Kwok Yung Yuen , Kai Wang Kelvin To , Shuofeng Yuan , Fuk Woo Jasper Chan , Jinxia Zhang , Fan Ngai Hung , Johnson Yiu-Nam Lau

IPC: A61K39/145 , A61K8/55 , A61K9/00 , A61K31/16 , A61K31/685 , A61K39/00 , A61K39/215 , A61K47/54 , C12N7/00 , C12Q1/70 , G01N33/94

Abstract: Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

5.

发明公开
COMPOSITIONS FOR ORAL CANCER OR AN OROPHARYNGEAL CANCER 审中-公开

公开(公告)号：US20240342203A1

公开(公告)日：2024-10-17

申请号：US18750831

申请日：2024-06-21

Applicant: GR BIOSYSTEMS, INC.

Inventor： Andrew J. GROSS , Shane RIRIE

IPC: A61K31/7034 , A61K9/00 , A61K31/12 , A61K31/121 , A61K31/16 , A61K31/4164 , A61K31/43 , A61K31/65 , A61K31/7048 , A61K31/7052 , A61K31/7056 , A61K47/34 , A61P35/00

CPC classification number: A61K31/7034 , A61K9/0014 , A61K9/0053 , A61K9/0063 , A61K31/12 , A61K31/121 , A61K31/16 , A61K31/4164 , A61K31/43 , A61K31/65 , A61K31/7048 , A61K31/7052 , A61K31/7056 , A61K47/34 , A61P35/00

Abstract: The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

6.

发明授权
Tetrahydrocurcumin compositions, methods of making, and methods of using the same 有权

公开(公告)号：US12115138B2

公开(公告)日：2024-10-15

申请号：US16811759

申请日：2020-03-06

Applicant: RENIBUS THERAPEUTICS, INC.

Inventor： Donald Jeffrey Keyser , Alvaro F. Guillem , Bhupinder Singh , Richard A. Zager

IPC: A61K31/12 , A61K9/127 , A61K31/145 , A61K31/16 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/7048 , A61K47/10 , A61K47/24 , A61K47/34

CPC classification number: A61K31/12 , A61K9/127 , A61K31/145 , A61K31/16 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/7048 , A61K47/10 , A61K47/24 , A61K47/34

Abstract: The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.

7.

发明授权
Integrin agonists or activating compounds and methods for making and using same 有权

公开(公告)号：US12109263B2

公开(公告)日：2024-10-08

申请号：US17471922

申请日：2021-09-10

Applicant: 7 Hills Pharma LLC

Inventor： Robert W Strozier

IPC: A61K39/39 , A61K31/16 , A61K31/381 , A61K31/404 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K39/00 , A61K47/60 , A61P37/04

CPC classification number: A61K39/39 , A61K31/16 , A61K31/381 , A61K31/404 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K39/0011 , A61K47/60 , A61P37/04 , A61K2039/55511

Abstract: Small molecule integrin agonists or integrin activating compounds including at least one di-alkylaryl amine end group and at least one alkyl or alkenoxy linking group including at least one protonatable moiety, wherein the compounds enhance vaccine efficacies, enhance adoptive cell therapy efficacies, enhance immunotherapy efficacies, enhance therapeutic antibody therapy efficacies, enhance checkpoint inhibitor therapy efficacies, enhance effector cell therapy efficacies, and enhanced cell based transplant efficacies and wherein at protonatable moiety either protonate at biological pHs or bears a charge with associated pharmaceutically acceptable counterion making the compound water soluble to improve bioavailability and methods for making and using same.

8.

发明公开
COMPOSITIONS AND METHODS FOR MODULATING HEXIM1 EXPRESSION 审中-公开

公开(公告)号：US20240307332A1

公开(公告)日：2024-09-19

申请号：US18528397

申请日：2023-12-04

Applicant: CASE WESTERN RESERVE UNIVERSITY

Inventor： Bin SU , Monica M. MONTANO

IPC: A61K31/18 , A61K31/16 , A61K45/06

CPC classification number: A61K31/18 , A61K31/16 , A61K45/06

Abstract: A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula,

and pharmaceutically acceptable salts thereof.

9.

发明公开
FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME 审中-公开

公开(公告)号：US20240277649A1

公开(公告)日：2024-08-22

申请号：US18623536

申请日：2024-04-01

Applicant: Epitracker, Inc.

Inventor： Stephanie Venn-Watson , John Reiner , Richard Lumpkin

IPC: A61K31/20 , A61K31/16 , A61K31/41 , A61K31/421 , A61K31/4245

CPC classification number: A61K31/20 , A61K31/16 , A61K31/41 , A61K31/421 , A61K31/4245

Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.